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I. Literature Review: 
ABSTRACT 
 
Background: Little is known about United States (US) physicians’ understanding and utilization 
of global CHD risk assessment in clinical practice. 
Purpose: To assess the current level of evidence regarding physicians’ use of global CHD risk 
assessment in primary prevention of cardiovascular disease by examining if there are valid and 
reliable tools available for clinicians to calculate patients’ global CHD risk scores, if calculation 
and communication of global risk scores translate into improved patient level outcomes, and if 
physicians understand/use global risk scoring in primary prevention of CVD. 
Methods: The MEDLINE database (from inception to 20 March 2010) was searched for studies 
involving physicians’ use of global CHD risk scores. Studies of any design were considered 
using the search terms, ―global coronary heart disease risk score‖, ―cardiovascular disease‖, 
―primary prevention‖, and ―physicians‖. Reference lists from related systematic reviews and 
primary articles were searched and additional citations were provided by experts in the field of 
cardiovascular disease prevention. Studies were limited to those written in English.  
Results: The search resulted in one good quality recent systematic review that assessed the tools 
available for calculation of CHD risk scores, two good quality recent systematic reviews of the 
literature that assessed whether global CHD scoring results in improved patient outcomes, and 
three poor to fair quality original physician survey studies that examined physicians’ use of 
global CHD risk scores.   
Conclusion: Available evidence suggests that there are many accurate, easy to use tools available 
to physicians for calculation of patients CHD global risk score. Global CHD risk scoring may 
increase prescribing of preventive therapy (aspirin and lipid lowering therapy), reduce CHD risk 
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factors over the short-term, and improve the accuracy of risk perception with no reported clinical 
harm. Physicians may also overestimate the absolute risk of CHD events and effects of 
preventive therapy and could benefit from interventions to increase acceptance of tools used to 
calculate CHD risk.  
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Inroduction: 
The goal of this review was to systematically assess the current level of evidence 
regarding physicians’ use of global CHD risk assessment in primary prevention of cardiovascular 
disease (CVD). Specifically I sought to answer three questions: (1) Are valid and reliable tools 
available for clinicians to calculate patients’ global CHD risk scores? (2) Do calculation and 
communication of global risk scores translate into improved patient level outcomes? (3) Do 
physicians understand/use global risk scoring in primary prevention of CVD? 
Selection of Articles: 
To identify relevant articles I searched the MEDLINE database from inception to 20 
March 2010 for studies involving physicians’ use of global CHD risk scores. I combined search 
terms for global coronary heart disease risk score, cardiovascular disease, primary prevention, 
and physicians and I limited the search to English language articles. I also reviewed reference 
lists from related systematic reviews and primary articles and additional citations were provided 
by experts in the field of cardiovascular disease prevention.  
Articles of any study design were considered in the search. All abstracts were reviewed 
and articles were excluded if they were deemed not applicable to the study questions based on 
the study populations, interventions, or outcomes assessed. The search resulted in six research 
articles addressing the three clinical questions. Three original physician survey studies examined 
physicians’ use of global CHD risk scores, two recent systematic reviews of the literature 
assessed whether global CHD scoring results in improved patient outcomes, and one recent 
systematic review assessed the tools available for calculation of CHD risk scores.  
Study Quality Assessments: 
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Quality ratings were assigned to each of the six included studies in our review. Quality 
ratings for the three survey studies were based on a scale from 0-2 (0 = poor, 1 = fair, 2 = good) 
and assessed overall potential for selection bias, measurement bias, appropriate analysis of the 
data, and generalizability of the findings from each study.  The potential for selection bias in 
each study was assessed by identifying the source population and determining whether it was 
adequately described and whether the study population was a representative sample of the source 
population. Additionally, due to the survey design of each study, non-response error was 
assessed and included in the determination of overall potential for selection bias. Measurement 
bias was assessed by the authors’ descriptions of how each survey was developed, piloted and 
validated. When available, the individual surveys were also read to assess the likelihood of 
measurement error. This was also taken into account for each measurement quality grade. The 
quality of analysis for each study was assessed by demonstrating use of appropriate statistical 
methods as well as acknowledgement of, and controlling for, potential confounding factors. 
Lastly, the grade for potential external validity of each study was given based on the studies 
applicability to populations outside the study and source populations.  
Quality ratings for the three systematic reviews were also based on a scale from 0-2, as 
described above. Each systematic review was judged on the completeness of the literature 
search, appropriate reporting of inclusion/exclusion criteria for the studies reviewed, whether a 
standard appraisal method was used to judge the internal validity of each study in the review, 
whether an appropriate analysis of the data was done, and lastly, whether heterogeneity between 
included studies was assessed.  
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Results:  
(1) Are valid and reliable tools available for clinicians to calculate patients’ global CHD 
risk scores? 
One recent systematic review by Sheridan, Pignone, and Mulrow1 , reviewed the available 
CHD risk calculation tools based on Framingham equations to help guide providers in selecting 
the best tools for their practices. They searched articles and websites to identify tools available, 
determine the accuracy of the available tools when information about sensitivity and specificity 
were given, and to determine the feasibility using these tools in clinical practice. Overall, they 
identified many available tools in a variety or formats available to clinicians including: risk 
charts, calculators for PDA’s, spreadsheet programs for computers, and web-based calculators. 
Some of the web-based tools also included individualized evidence based treatment guidelines 
with the calculated risk score. Most of the tools they identified displayed good to excellent 
sensitivity and specificity for the detection of patients at increased CHD risk; however, data 
available to complete the Framingham calculations in these studies was insufficient in 5-49% of 
cases with no imputation of average risk factor information to account for this in the analyses.  
The review provided evidence to suggest that physicians have many available options for 
calculating a global CHD risk score. A comprehensive search of the literature was done, 
although, no mention was made as far as search terms used for identification of websites. They 
only included tools and studies examining tools that were based on the full Framingham 
equations. They appropriately excluded websites that required membership or log-in as it is 
unlikely that physicians will take the time to provide this type of information to simply use a 
calculator. They also appropriately excluded articles that did not provide enough information to 
calculate the sensitivity and specificity of a tool, when this information wasn’t explicitly given. 
 8 
 
They were unable to compare sensitivities and specificities across studies as there were varying 
numbers of indeterminate assessments, difference reference standard cut points, and diverse 
study populations.  
(2) Does the use of global CHD risk scoring translate into improved clinical outcomes for 
patients? 
I identified two recent systematic reviews conducted in the U.S. that examined the effect 
of giving global CHD risk information to physicians and patients on clinical outcomes.  
The first review by Sheridan, Viera et. al2 , included 14 studies that assessed the effects of 
providing global CHD risk information to individuals. They defined the effect of providing 
global risk scores in terms of four clinical outcomes: accuracy of risk perception, intent to start 
therapy, adherence to therapy, and reduction in CHD risk factors and predicted CHD risk. Their 
review showed that providing global risk information either alone or in combination with 
education or counseling, increased the accuracy of perceived risk. Importantly, none of the 
studies that examined this outcome included a control group with no risk presentation given. 
Also, the authors noted that the effect sizes varied. Studies that analyzed the outcome of intent to 
start preventive therapy showed that providing global CHD risk information increases intent to 
start therapy by 15-20 absolute percentage points, and that larger effect sizes are seen when risk 
information is accompanied by counseling versus education alone. They included one small 
cluster randomized trial that assessed the effect of giving global CHD risk information on 
adherence to therapy. This trial showed that there was an increase (non-statistically significant) 
in adherence to decisions to take statins among those who were randomized to receive a global 
risk score plus risk factor education versus education alone and that  provision of global CHD 
risk score plus education reduced the number of missed doses of statins over a week compared 
 9 
 
with education alone; however, this study provided the intervention at only one time point, 
analyzed adherence as a secondary outcome, lacked statistical power, and did not adjust for 
baseline differences in CHD risk. Lastly, for studies analyzing change in predicted CHD risk 
they found mixed effects of providing global CHD risk information on changes in predicted 
CHD risk that were related to the intensity of the intervention. They reported that studies using 
repeated global risk score presentation or repeated bouts of counseling showed 0.2-2% 
reductions in predicted 10-year risk. 
This was a methodologically strong review of 18 trials inclusive of over 24,000 patients. 
Their literature search was comprehensive, clearly outlined, and included searches on multiple 
databases, hand searching of bibliographies, expert consultation, and related articles searches. 
Appropriate inclusion and exclusion criteria for the studies they selected were clearly articulated. 
Studies were only included in the review if they specified global CHD risk information 
presentation directly to individuals as a primary intervention and measured one of their outcomes 
of interest. They used a standard appraisal method to assess study quality. Two independent 
reviewers assessed the full text articles and assigned a grade of poor, fair, or good. These grades 
were converted to numerical values (poor = 0, fair = 1, good = 2) that held equal weight for each 
aspect of internal validity being judged. The scores for each study were then combined and 
averaged for a final quality rating. Meta-analysis was not done in this review due to the 
heterogeneity in study designs, study populations and outcomes measured; however, evidence 
tables were reported for each outcome.  
The second review by Sheridan and Crespo3 , analyzed 11 total studies inclusive of over 
15,000 patients and over 600 physicians. The aim of the review was to examine whether 
physician knowledge of a patient’s global CHD risk score a clinical outcomes. Their primary 
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question examined clinical benefits, as they defined them, of a physician’s knowledge of 
patients’ global CHD risk score. They also included studies that examined harms associated with 
screening using global risk scores as a secondary question. They found that in high risk patients, 
physician knowledge of CHD risk is associated with increased prescribing of cardiovascular 
drugs, and improvements in blood pressure. They also reported that one study found no 
improvement in proportion of patients at high risk; however, this may have been attributed to the 
large number of patients at high baseline risk in the study. No studies examined the effect of 
global risk calculation on actual CHD outcomes and the remaining studies in their review were 
too methodologically limited to draw significant conclusions. No clinical harms were associated 
with a patient’s knowledge of their CHD global risk score when presentation was followed by 
scheduled follow-up or counseling.  
Their conclusions were based on six fair quality, and five methodologically limited 
studies. They outlined a meticulous search of the literature that included a MEDLINE database 
search with hand searching of bibliographies and related articles searches. Articles with the 
primary intervention of global CHD risk calculation with clear documentation of calculation of 
CHD risk scores by a physician or other healthcare provider as part of an individual patient 
encounter were the only studies included in their review. The study endpoints they examined 
were clinically appropriate for both the benefits and harms of global CHD risk calculation. They 
included studies of any design in their search and were unable to statistically analyze pooled data 
due to the heterogeneity in the study designs and their interventions. Quality ratings for the 
studies included were adapted from the U.S. Preventive Services Task Force. Two independent 
reviewers assessed the quality of each study and averaged together the individual quality ratings. 
They clearly outlined criteria for assessing the internal validity of included studies as well.  
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(3) Do physicians understand/use global risk scoring in primary prevention of CVD? 
I identified three original physician survey studies that met the criteria for inclusion in 
this review that assessed physicians’ ability to accurately predict patients global CHD risk score 
and whether CHD risk scoring is used in clinical practice. One study also assessed the barriers to 
implementation of risk scoring in physicians who reported never or rarely using global CHD risk 
scoring.  
The first article by Pignone, Phillips, Elasy and Fernandez4  examined physicians’ ability 
to predict the risk of CHD events and the effect of lipid lowering therapy for 12 hypothetical 
primary prevention scenarios concerning patients with different levels of CHD risk. Each 
scenario also asked the physician to rate on a 4-point Likert scale whether or not they would 
recommend lipid lowering therapy for that patient. The authors found that overall; the 5-year 
CHD risk estimates provided by the physicians were accurate for only 24% of the total 
responses. Of the responses that were inaccurate, 66% were overestimates while 10% were 
underestimates of risk. When the physicians were asked to report the relative risk reduction after 
the patients in each scenario were provided lipid lowering therapy, 43% of their estimates were 
considered accurate. They also reported that most physicians recommended lipid lowering 
therapy in every scenario except one.  
The authors used a convenience sample of internal medicine residents at three university 
sites. They recruited a total of 79 respondents by offering an invitation to a lunch. In an effort to 
increase the validity of their findings, they mention that they did not inform the physicians of the 
specific nature of the study prior to the lunch meeting; however, it is mentioned that the 
physicians were invited to a lunch where they would fill out a survey on preventive care. It is 
possible that those who participated in the survey were more interested in preventive care 
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compared to those physicians who did not attend the lunch meeting. Furthermore, of those who 
completed the survey, 53 were residents, 8 were fellows, and 18 were attendings.  It is plausible 
that the difference in knowledge from resident to fellow to attending physician could have biased 
the results of the survey as it possible that an attending would more accurately estimate a patients 
CHD risk than a first year resident. The external validity of their results is fair at best as they 
used a convenience sample of university physicians that is not representative of the general 
physician population.  
The author’s pilot tested their survey, balanced the number of scenarios involving low, 
intermediate, and high risk patients, and based the answers on Framingham data. Every physician 
received the same survey and there was no mention of blinding. Their analysis was appropriate, 
and they did not attempt to compare the results of residents vs. attendings or cardiologists vs. 
general internists as their sample size was too small. They also made no mention of how their 
accuracy grade cut-offs were determined, or what they did in the case of incomplete survey data. 
Lastly, it is important to note that the physicians completing the survey were not allowed to use 
any form of risk calculator or chart to help them predict the patients CHD risk. Even when the 
authors attempted to control for the inherent lack of precision by setting an accuracy threshold, 
the majority of physicians failed to appropriately estimate CHD risk.  
In summary, in a small convenience sample of university physicians (mostly residents), 
the 5-year risk of CHD is largely overestimated, especially in the lower risk populations. 
Furthermore, lipid lowering therapy was inappropriately suggested by the majority of survey 
respondents. Although likely not very generalizable, this study highlights the need for risk 
prediction calculators or charts to assist physicians with CHD risk estimation.  
 13 
 
In a second study by Persell, Zei, Cameron, Zielinski, and Lloyd-Jones5 , 202 primary 
care physicians who had an academic affiliation with Northwestern University’s Feinberg School 
of Medicine were mailed surveys to determine how providing 10-year CHD risk estimates 
influenced preventive cardiology decision making and whether providing lifetime risk 
information had any significant impact. Each survey had five clinical scenarios presented in three 
ways: first with only risk factor information, then with the addition of a calculated 10-year CHD 
risk score, then with the addition of lifetime CHD risk. The physicians were then asked, after 
each iteration, whether they would prescribe low-dose aspirin, at what interval they would repeat 
lipid testing, and at what LDL cholesterol level they would prescribe lipid lowering therapy. 
Their answers were compared to contemporary guidelines.  
Overall, the authors found that 37% of the primary care physicians in their study reported 
using risk calculating tools never or rarely to make primary preventive treatment decisions. 
Furthermore, they often made preventive treatment decisions that were not guideline concordant. 
While most recommended aspirin when the short term coronary risk was low, 20% did not 
recommend it for a male with a 10-year coronary risk of 15%. For patients not at goal LDL, the 
physicians recommended repeat testing less promptly than recommended by guidelines, and for 
patients at goal LDL they recommended repeat testing more frequently than guideline 
recommendations. Provision of 10-year CHD risk estimates increased guideline concordant 
prescribing slightly, but most physicians who gave guideline discordant responses did not change 
their answer when they were given the 10-year risk information. Adding lifetime risk 
information did not alter physicians’ aspirin prescribing decisions appreciably, but did lead more 
physicians to recommend guideline discordant lipid therapy at lower LDL levels.  
 14 
 
The authors of this study achieved a 49% response rate (99 total physicians) to their 
survey with all included physicians having affiliation with the medical school. They reported that 
8% of the non-responders were full-time medical school faculty members compared to 28% of 
the responders. The potential for significant non-response error is present in this study as the 
authors failed to give any demographic information for the non-responders. They also did not 
report any information regarding the generation of their survey and whether it was pilot tested 
prior to deployment raising the likelihood of potential measurement error. The survey also did 
not have the ability to restrict the physicians from going back to previous questions after they 
were provided with the different risk levels. The survey was based on valid aspirin and lipid 
screening/treatment guidelines and all physicians received the same survey. 90-95% of 
physicians responded to all three scenarios for each question but no mention is made of how 
incomplete surveys were handled. The generalizability of their results was fair at best, as all 
physicians were affiliated with one medical center in one city.  
In summary, many physicians reported never using CHD risk calculating tools when 
making primary preventive prescribing decisions. Additionally, even when physicians were 
presented with 10-year CHD risk estimates, their prescribing and screening behaviors were 
largely unchanged. It may be important for risk estimation tools to include guideline concordant 
decision support along with risk estimations to aid clinicians in prevention decisions.  
The third physician survey study by Eichler, Zoller, Tschudi, and Steurer6 , was a postal 
survey mailed to 772 general internists in two regions in Switzerland. The authors collected data 
on the frequency of use of CHD risk calculation and then asked physicians to select from a set of 
potential barriers to the use of global risk calculation. Of the 356 surveys included in the study, 
73.9% (263) of respondents reported that they rarely or never used global CHD risk scoring in 
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clinical practice. The most common barriers to the use of CHD risk scoring reported were: the 
feeling that a single risk value does not take into account the complex situation of the patient, 
that the results of prediction rules may lead to overtreatment, that ―I know my patients well 
enough‖ to estimate their risk without prediction rules, and that the results of prediction rules are 
not helpful for decision making in practice. Interestingly, the authors pointed out that while 58% 
of physicians argued that a single risk value derived from risk calculations is an 
oversimplification, 46% of physicians reported using information derived from a single risk 
factor to guide preventive therapy.  
The authors of this study employed a much larger sample size than that used in previous 
studies. They achieved a 49% response rate with a final sample size of 356. Although they did 
sample a large number of physicians from different regions of the country, no characteristics of 
non-responders were reported. It is possible that the true rate of global CHD risk scoring among 
Swiss physicians may be even lower as motivated physicians may have been over-represented in 
this study. Although no pilot testing was done to assess the validity and internal consistency of 
their survey, they outlined an extensive development process for their survey. They also reported 
that each questionnaire was done quasi-anonymously and that the authors were blinded from the 
names of responders. They used simple descriptive statistics to report their findings; however, 
didn’t mention how missing responses were handled in the analysis. The generalizability of their 
results was fair and it is unclear how the attitudes of physicians in Switzerland compare to those 
of physicians in the U.S and other countries. 
In summary, the authors proposed that the rejection of using global CHD risk scoring in 
practice was based on the overall judgment that statistical risk information seems incompatible 
with comprehensive and individualized patient care. This study indicates that educational 
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interventions are needed to increase the acceptance of these tools in clinical practice in 
Switzerland. While this may also be valid in the U.S., more data is needed on U.S. physicians 
attitudes regarding CHD risk scoring. 
Conclusion: 
 Overall, the evidence from the studies reviewed reveal that physicians have difficulty 
assessing a patient’s global CHD risk and making prescribing decisions based on this risk. These 
studies also showed that many physicians in Switzerland do not use global CHD risk scoring and 
harbor negative attitudes towards its application in clinical practice. Presenting global CHD risk 
to patients can improve the accuracy of their perceived risk and may also increase intent to 
initiate preventive therapy. Furthermore, physicians’ use of global CHD risk scoring may 
increase prescribing of preventive medications and decrease CHD risk factors in the short-term. 
Finally, many valid, reliable tools are available in a variety of formats to aid physicians in 
accurately assessing a patient’s global CHD risk score.  
 Further study is needed to accurately determine the utility of global CHD risk scoring in 
clinical practice. Although most of the studies included were methodologically good, it is 
difficult to draw significant conclusions from small, non-representative samples. It would be 
beneficial to obtain information regarding the understanding and utilization of, and attitudes 
towards, global CHD risk scores in a large random sample of physicians in the U.S. Data from 
such a study could give insight into the barriers to use of global CHD risk scores and guide the 
development of potential educational interventions to increase guideline concordant CVD 
primary preventive practices.  
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ABSTRACT 
 
Background: Use of global coronary heart disease (CHD) risk assessment is recommended to 
guide primary preventive pharmacotherapy; however, little is known about United States (US) 
physicians’ understanding and utilization of global CHD risk assessment in clinical practice.  
Purpose: This study examined US physicians’ self-reported knowledge and attitudes about global 
CHD risk calculations, characteristics associated with global CHD risk assessment use, and 
whether global CHD risk assessment is used to guide primary preventive therapy 
recommendations. 
Methods: Using a web-based survey of US family physicians, general internists, and 
cardiologists, we examined awareness of tools available to calculate CHD risk, perceptions of 
10-year CHD risk levels that corresponded to high and low risk, and frequency of using global 
CHD risk to guide prescription of aspirin, lipid-lowering and blood pressure (BP) lowering 
therapies for primary prevention. Likert-scales of 0 (lowest) to 5 (highest) were used to assess 
self-reported attitudes and importance of barriers to use of CHD risk assessments. Characteristics 
of physicians indicating they use CHD risk assessments were compared in unadjusted and 
adjusted analyses. 
Results: A total of 952 physicians completed the questionnaire. Of those responding to each 
question, 100% reported awareness of tools available to calculate CHD global risk scores and 
over 80% agreed that CHD risk calculation is useful, improves patient care, and leads to better 
decisions about recommending therapies for CVD prevention; however, only 41.4% of 
physicians use CHD risk assessment. The major barrier to CHD risk assessment is that it is too 
time consuming (mean importance rating 2.6). 40% of respondents who calculate global CHD 
risk indicated they use it to guide lipid lowering therapy recommendations; 35% use it to guide 
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aspirin therapy recommendations; and 32% use it to guide BP lowering therapy. Only 39% of 
respondents routinely tell patients their risk score. Physicians who use CHD risk assessments 
were more likely to classify high and low risk patients in accordance with current guideline 
thresholds. Physicians who use PDAs were most likely to use CHD risk assessments (adjusted 
OR 1.54; 95% CI 1.15-2.05).   
Conclusion: Awareness of tools to calculate global CHD risk is high, but the majority of 
physicians do not use CHD risk assessments in practice. Perceptions of CHD risk levels 
corresponding to high and low risk are more consistent with guidelines for physicians using 
CHD risk assessments. A minority of physicians utilize global CHD risk to guide prescription 
decisions or patient motivation. Use of PDAs by physicians may increase use of CHD risk 
assessment tools. 
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INTRODUCTION 
 
Coronary heart disease (CHD) was the cause of one out of every six deaths in the U.S. in 
2006 and is the largest major killer of American males and females.7  Remarkably, CHD is also 
largely preventable. According to a case control study of 52 countries, nine easily measured and 
potentially modifiable risk factors account for over 90% of the risk of an initial acute myocardial 
infarction (MI).8  Unfortunately, the majority of individuals with elevated CHD risk factors are 
not using appropriate risk reducing therapies.2  One contributing factor is that clinicians often do 
not accurately estimate a patients risk for CHD.4   
 Primary prevention of CHD should be a top priority due to the high rate of first events 
that are fatal, disabling, or requiring of expensive management.9  The risk for the development of 
CHD varies greatly among individuals. Effective primary prevention of CHD therefore requires 
individualized interventions that range in intensity.  In order to appropriately select interventions 
for primary prevention it is necessary to stratify patients based on an assessment of risk for 
development of cardiovascular disease.10 While guidelines for the management of individual risk 
factors put forth by the Adult Treatment Panel report of the National Cholesterol Education 
Program, the Joint National Committee of the National High Blood Pressure Education Program, 
and the American Diabetes Association exist, these reports also promote adjustment of 
intervention intensity based on a patient’s global cardiovascular disease risk.10   Current 
guidelines suggest that all patients > 40 years of age or those with > 2 risk factors should have 
their 10-year risk of CHD assessed every 5 years or as risk factors change, with a global risk 
score.9  The risk factors used to calculate global CHD risk include: age, sex, smoking status, 
blood pressure, total cholesterol (sometimes LDL), HDL cholesterol, and in some risk tools, 
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diabetes.9  There are many user-friendly, easily accessible tools available for estimating a patients 
CHD risk including risk charts and risk calculators for personal digital assistants, personal 
computers, and web-based use.1  When compared to the full Framingham equations for 
identifying patients at increased risk, these tools are generally very accurate.1  
 Effective classification of a patients’ risk for CHD has many advantages in clinical 
practice. Firstly, global risk calculation allows improved prediction of incident events. 
Furthermore, physicians armed with a better understanding of a patient’s actual risk of 
developing CHD are better able to identify patients at high risk who need immediate 
intervention.3  Global risk scores also provide a reference to help physicians compare the risks of 
an intervention to the benefits it may provide the patient. Use of global risk may also improve 
intermediate and long-term outcomes for patients.3  Patients may gain an improved understanding 
of their risk and the reason for any proposed interventions, which may increase motivation to 
adhere to any preventive medications that are prescribed.3    
 While the advantages to using global risk assessment in the primary prevention of CHD 
have been documented and recommended for use in clinical practice, little is known about the 
actual use of global CHD risk in clinical practice. The purpose of this study was to examine U.S. 
physicians’ understanding and utilization of global CHD risk assessments when considering 
clinical interventions for primary prevention.  
METHODS 
 
Overall Design 
 
 This study was a cross-sectional, web-based survey of a national sample of family 
physicians, general internists, and cardiologists. The survey was designed by the investigators, 
pretested among a convenience sample of family physicians, general internists, and cardiologists, 
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and automated by survey experts at the Odum Institute for Research in Social Science affiliated 
with the University of North Carolina at Chapel Hill. Data on physician’s awareness and 
attitudes about global CHD  risk scores and reported use of such scores in primary 
cardiovascular disease prevention were collected through the web-based questionnaire. This 
study was approved by the Institutional Review Board of the University of North Carolina at 
Chapel Hill. 
Study Sample and Invitations to Participate 
 The sampling frame was family physicians who are members of the American Academy 
of Family Physicians (AAFP) and general internists and cardiologists who are members of the 
American College of Physicians (ACP). A mailing list of 9000 members randomly selected from 
a database of members of the AAFP (family physicians) and the ACP (general internists and 
cardiologists) was obtained. The list consisted of 2623 family physicians (377 members were 
excluded because they were medical students), 3000 general internists, and 3000 cardiologists.  
Personalized letters of invitation were mailed to the 8623 physicians. These letters 
described the study and provided a URL for the online survey with an individualized 
identification code to allow tracking of non-responders. At two and four weeks after the initial 
invitation was sent out, non-respondents were mailed reminder letters. As an incentive to 
participate, physicians who wished to do so could have their name entered into a drawing for one 
of two $500 gift cards.  
Variables 
Data obtained from the survey included physicians’ awareness of tools available to 
calculate CHD risk scores, perceptions of what 10-year CHD risk levels corresponded to ―low 
risk‖ and ―high risk‖, frequency of using CHD risk score in clinical practice and how often CHD 
 23 
 
risk scores are used to guide prescription of aspirin, lipid-lowering and blood pressure lowering 
therapies for primary prevention. Additionally, we collected data on attitudes regarding the 
usefulness of CHD risk scores, and among those who reported not using CHD risk scores, 
reasons for not doing so. Information regarding respondents’ specialty type, sex, year of 
graduation from medical school, amount of patient care time, type of practice setting, region of 
the country, use of electronic medical records and computers in exam rooms, and use of a 
personal digital assistant (PDA) during patient encounters was also collected. 
Analysis 
 Responses to each of our items were tabulated, and differences were compared by respondent 
characteristics. Testing for significant differences was performed using analysis of variance 
(ANOVA) for Likert-scaled outcomes and chi-square for categorical outcomes. Attitudes 
towards CHD risk scoring were examined using five statements about CHD risk scoring. 
Physicians responding, ―Strongly Agree‖, or Agree‖ were combined into an ―Agree‖ category, 
while subjects who responded, ―Disagree‖ or ―Strongly Disagree‖ were combined into a 
―Disagree‖ category. Proportions agreeing with each statement were tabulated and compared 
between specialty groups. Characteristics of physicians who indicated that they ―occasionally‖, 
―most of the time‖, or ―always‖ obtain a calculation of a patients global CHD risk for primary 
prevention were compared in unadjusted analyses and then by logistic regression to adjust for 
specialty, years in practice, amount of patient care time, and PDA use.  
 Among respondents indicating ‖never‖ or ―rarely‖ calculating a patients global CHD risk 
score, potential reasons were examined through responses to six statements that were graded for 
importance on a Likert-scale from 0-5 (with 0 being not important at all- 5 being extremely 
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important). The ratings were averaged for each statement and compared in unadjusted analyses 
by specialty. 
  The percentage of physicians responding to two questions aimed at classifying a high and 
low risk patient based on CHD risk score were examined by comparing the responses of 
respondents who routinely use CHD risk scoring for primary prevention and those who do not.  
The percentage of physicians who chose the single high and low guideline concurrent 
Framingham-based risk thresholds (> 20% for high risk and < 10% for low risk) was also 
examined. Physicians’ use of CHD risk scoring to guide primary preventive pharmacological 
therapy was examined as well. Respondents indicating that they use CHD risk scoring 
―Occasionally‖, ―Most of the time‖, or ―Always or Nearly Always‖, were categorized as those 
who use CHD risk scoring to guide preventive therapy and were compared to those do not. 
Results were also compared by specialty. Statistically significant differences were defined as a p-
value <0.05. To assess the potential for nonresponse bias, geographic regions between 
respondents and non-respondents were compared.  All analyses were performed using Stata 10.1 
statistical software (StataCorp, College Station, TX). 
RESULTS 
Study Participants 
A total of 1238 physicians participated in the survey. Respondents who indicated they did not 
see patients in the office setting (n=251) or whose practicing specialty was one other than family 
medicine, general internal medicine, or cardiology (n=55) were excluded. Of the remaining there 
were 74 undeliverables (including 8 returned due to deceased recipient), and 3 refusals. The 
adjusted response rate was 15%. The final sample consisted of 390 family physicians, 272 
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general internists, and 290 cardiologists. Nonrespondents were compared to respondents by 
geographic region, and the two groups were very similar (Appendix D).  
Of those who responded, the majority were male (74%), spent more than 75% of work time 
in office based patient care (56%), use EMR in their practices (59%), have computers in patient 
exam rooms (56%), and have been in practice for 10 years or more (79%) (Table 1). Small group 
practices were the most common practice setting (32%), and the most common region of the 
country practiced in was the South region (33%). Cardiologists (94%) who responded were more 
likely than general internists (75%) and family physicians (58%) to be male. Cardiologists (88%) 
were also more likely than general internists (70%) or family physicians (40%) to have been in 
practice for more than 20 years. General internists and family physicians spent more time in 
office-based care than cardiologists. Family physicians (62%) were more likely than general 
internists (37%) and cardiologists (38%) to use a PDA when seeing patients in the office.   
Awareness and Use of Tools to Calculate Global CHD Risk 
All physicians (N=839) who responded to the question, ―Have you heard about tools to 
calculate a patients overall risk of coronary heart disease in the next 10 years (global CHD 
risk)?‖ responded yes (100%).  Approximately 41% of respondents reported using global CHD 
risk at least occasionally when considering primary prevention of CHD in adults, including 8% 
who reported always or nearly always doing so.  One third of respondents (33%) who use global 
CHD risk in practice reported using a web-based application, while 29% use a paper chart and 
25% use a program on a PDA to obtain their patient’s risk estimate. Few (13%) use other 
methods such as non-web based computer programs (e.g., a spreadsheet) and calculators 
embedded in EMRs.  
 26 
 
 The majority of respondents (with no significant difference between specialties) agreed or 
strongly agreed that global CHD risk calculation is useful, improves patient care, leads to better 
decisions about whether or not to recommend therapies to prevent heart disease events, and 
increases the likelihood that they will recommend risk reducing therapies to prevent heart disease 
(Table 2). However, a minority actually reported using global CHD risk to guide their primary 
preventive pharmacotherapy recommendations. Approximately 40% of respondents who 
calculate global CHD risk indicated they use it to guide lipid lowering therapy recommendations; 
35% use it to guide aspirin therapy recommendations; and 32% use it to guide blood pressure 
lowering therapy (Table 3). Cardiologists were more likely to report using CHD risk to guide 
lipid lowering therapy.  
Approximately 39% of respondents who use CHD risk calculation reported that they tell their 
patients his/her CHD risk estimation, ―most of the time‖, ―nearly always‖, or ―always‖.  
Cardiologists were more likely to tell a patient his/her CHD risk estimation (49%) than were 
family physicians and general internists (36% and 32% respectively) (p<.001).  
Physicians who Use Global CHD Risk Assessments 
 Physicians’ reports of using global CHD risk assessments differed by specialty, years in 
practice and time spent in office-based care (Table 4). Among cardiologists, 49% reported using 
global CHD risk assessments, while approximately 42% of family physicians and 32% of general 
internists reported using such assessments (p<0.001). Those who had been in practice for 10-19 
years (50%) were more likely than those who have been in practice for less than 10 (41%) and  
more than 20 years (39%) to use CHD risk assessments (p=0.02). Respondents who reported 
spending 50% of time in office based care (58%) were more likely than those spending >75% 
(36%), 51-74% (51%), 25-49% (44%) and <25% (40%) of time in office based care to use global 
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CHD risk assessments (p=0.002).  Those who indicated they used a PDA when seeing patients 
were more likely to report using global CHD risk assessments (47% vs. 36% , p=0.001). There 
were no differences in use of global CHD risk assessments among those who used EMRs or 
those who had computers/internet connection in exam rooms.  After adjusting for specialty, years 
in practice, office based care time, and PDA use, physicians who reported using a PDA were 
more likely to use CHD risk assessments than those who reported not using a PDA in practice 
(OR 1.54; 95% CI 1.15-2.05). Specialty was also an independent predictor of CHD risk 
assessment use with cardiologists more likely to use CHD risk assessments, followed by family 
physicians and general internists respectively (OR 1.45; 95% CI 1.19-1.75).  
Physicians’ Perceptions of CHD Risk Levels 
 When asked, ―At what level of risk do you consider a patient to be ―high risk‖ for CHD 
events based on 10-year CHD risk levels?‖, 36% of respondents chose a risk threshold of 10% or 
above, while 33% of respondents chose 20% or above (median 15% or above) (Figure 1). In 
response to the question, ―Below what level of 10-year CHD risk do you consider a patient to be 
―low risk‖ for CHD events?‖, 30% of physicians selected a risk threshold of 10% or less, while 
42% of physicians chose a risk threshold of 3% or less (median 6% or less). When physicians’ 
responses were compared to thresholds suggested by current guidelines (10-year CHD risk 20% 
or above = high risk, and 10-year CHD risk 10% or less = low risk)9, 11 , those who reported using 
CHD risk assessments were more likely to select the guideline concordant 10-year CHD risk 
threshold of 20% or above to indicate high risk (39% ), compared to those who reported not 
using CHD risk assessments (29%) (p=.002) (Figure 2). No differences were seen for 
respondents who selected a risk threshold below 20% to indicate high risk between those who 
use of CHD risk assessments and those who do not; however, those who selected a 10-year CHD 
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risk threshold higher than 20% to indicate high risk were significantly less likely to use CHD risk 
assessments compared to those who do (12% vs. 18% respectively) (p=.03). Similarly, 
physicians who used CHD risk assessments were more likely to select the guideline concurrent 
10-year CHD risk threshold of 10% or less to classify a ―low risk‖ patient (34%) than those who 
do not use CHD risk assessments (28%) (p=.04). No differences were seen for respondents who 
selected risk thresholds above and below 10% to classify a ―low risk‖ patient.  
Reasons for Not Using Global CHD Risk Assessments 
 Among physicians’ who reported not using CHD risk assessments (N=492), the reason 
with the highest mean importance rating (2.6 + 1.6) was, ―It is too time consuming‖ (Table 5). 
Family physicians (2.8) rated this reason higher than general internists (2.6) and cardiologists 
(2.3) (p=.02). The reason with the next highest mean importance rating was, ―I do not find it 
useful in practice‖ (2.2 + 1.6). Cardiologists (2.9) rated this reason higher than general internists 
(2.0) and family physicians (1.9) (p<.0001). Lack of familiarity with how to use the risk 
calculation and lack of easy-to-use tools were rated slightly less important, particularly by the 
family physician and general internist respondents. Lack of accurate tools and a perception that 
the risk calculation is not valid for [my] patients received ratings indicating they were the least 
important of the listed reasons. 
DISCUSSION 
 Our study found that among U.S. physicians: (1) awareness of tools to calculate CHD 
global risk is extremely high, (2) use of CHD global risk calculation in practice is low, (3) the 
main reason for not calculating a patients global CHD risk appears to be that it is too time 
consuming, (4) those who use global CHD risk tools more accurately select guideline concurrent 
risk thresholds to indicate high and low CHD risk, (5) use of global CHD global risk calculation 
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to guide primary preventive pharmacologic therapy is low and used to guide aspirin 
recommendations by less than a third of physicians.  
The major barrier to CHD risk assessment use is the perception that CHD risk assessment 
is too time consuming. It has been shown previously that one of the main barriers to delivery of 
preventive health services in primary care is lack of time.12  However, a study by Pollak, Krause, 
Yarnall, et al., found that even with limited time, primary care physicians address many ―A‖ 
rated preventive services adequately; including cholesterol and blood pressure management.12  
While lack of time during primary care patient visits is certainly a valid concern, there are many 
tools available that offer very quick and accurate calculation of a patients CHD risk score. 1  
Physicians in our study who use a PDA when seeing patients in the clinic were more likely to use 
CHD risk assessments than those who do not. This suggests a potential of CHD risk calculator 
programs for PDAs as a method of increasing CHD risk assessments among physicians. 
Fortunately, several  CHD risk calculation tools are already available for PDAs..1   
Cardiologists were most likely to indicate that CHD risk scoring is not useful in clinical 
practice, which could potentially be related to the lower proportion of patients seen for which 
primary prevention (rather than secondary prevention) is of concern. General internists and 
family physicians were more likely to indicate that they are not familiar enough with how to use 
CHD risk calculations, and that there are no accurate or easy tools available to calculate a CHD 
risk score. These responses suggest a need to develop educational interventions for physicians 
that discuss the use of global CHD risk calculations in clinical practice.
2
  
Our findings suggest that physicians using CHD risk assessment are more likely to have 
perceptions of risk that are concordant with current guidelines.9  This finding may translate to 
better decisions regarding pharmacotherapy for CVD prevention.  
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The U.S. Preventive Services Task Force has reported that the risk levels for which the 
benefits of aspirin therapy outweigh the potential harms is a 10-year CHD risk of >4% (> 3% for 
women) for patients aged 45-59 years, > 9% (> 8% for women) for patients aged 60-69 years, 
and >12% (> 11% for women) for patients aged 70-79 years.13  Additionally, statin use could be 
associated with an increase in mortality of 1% in 10-years, which is large enough to outweigh the 
beneficial effects of statins on CHD mortality in patients with a 10-year CHD risk of < 13%.14  
Due in part to these potential harms associated with preventive pharmacotherapy, calculating a 
patient’s global CHD risk is an important step, allowing adjustment of the intensity of risk factor 
management to the overall risk:benefit ratio for the patient.11 9 10  Still, in our sample, the majority 
of physicians reported they did not use CHD risk assessments to guide primary preventive 
pharmacotherapy decisions.  Overall, only 40% of respondents reported using CHD risk 
assessments to guide lipid lowering therapy and even less reported using it to guide 
recommendations for aspirin therapy. A recent study showed that when 10-year coronary risk 
information was given to physicians’ prescription of guideline concordant lipid-lowering and 
aspirin therapies was slightly improved.5    
In addition to its usefulness in helping clinicians and patients make decisions about 
preventive pharmacotherapy that take into account the balance of benefits and harms, global 
CHD risk could also be used to motivate patients.3  However, we found that less than 40% of 
those who use CHD risk assessments inform patients of their risk. Taken together, these findings 
indicate that only a slight majority of physicians (58%) who use CHD risk assessments use them 
to guide prescription decisions or inform patient of their risk. This suggests that even when CHD 
risk is calculated by physicians in practice, they may be unaware of how to utilize the CHD risk 
information.  
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Our findings illustrate the need for interventions to increase knowledge and acceptance of 
using global CHD risk assessment for guiding primary prevention of CVD. However, the type of 
intervention that is most effective remains unknown. The use of guideline concordant decision 
aids, programs embedded in EMRs that automatically calculate and display risk values and 
action thresholds, and risk charts in patient exam rooms are examples of system improvements 
that warrant further investigation.  
Limitations 
 The major potential limitation of this study is that of non-response bias. If physicians 
who responded to our survey were more interested in cardiovascular disease prevention 
compared to those who did not respond, then our results may be biased. Physicians who are more 
interested or passionate about primary prevention of CVD might be more likely to be aware of 
tools used to calculate global CHD risk and more likely to answer questions in agreement with 
the utility of global CHD risk score calculation. This would bias our results towards greater 
awareness and perceived usefulness of CHD risk assessments. Another potential limitation is that 
of sampling bias. If physicians who are members of the AAFP and ACP are different from 
physicians who choose not to be members, then our sample may not be reflective more generally 
of US physicians of the included specialties.  
Conclusions 
U.S. physicians’ awareness of tools to calculate global CHD risk is extremely high; 
however, the majority of physicians do not use CHD risk assessments in practice. A perceived 
barrier to using global risk calculation is that it is too time consuming. While perceptions of 
CHD risk are more in accordance with guidelines for physicians using CHD risk assessments, 
only a minority of physicians utilize CHD risk scores for guiding prescription decisions or 
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patient motivation. Use of PDAs by physicians may increase CHD risk assessment; however, 
educational interventions and system improvements are needed to improve U.S. physicians’ 
knowledge of global CHD risk and to support primary preventive therapeutic decisions.  
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III. Appendix A: Quality and Evidence Tables 
 
Table 1: Evidence Table for Studies examining physicians’ use/understanding of global CHD risk scores 
 
Study 
Authors, 
Year 
Study 
Design 
Source 
Population 
Study Population Intervention Significant Results 
 
Pignone, 
Phillips, Elasy 
and Fernandez4 
, 2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physicians 
Survey 
 
Physicians at three 
university sites  
 
79 respondents 
completed survey (53 
residents, 8 fellows, 18 
attending physicians) 
Mean age 31 years, 65% 
men,  
Of 8 fellows and 18 
attending physicians 
77% were general 
internists, 23% were 
cardiologists 
 
 
Potential respondents were invited to a lunch meeting  
(volunteers) in which they would complete a survey on 
preventive care 
Survey with 12 clinical scenarios of differing 5-year 
risk levels (4 low risk, 4 int risk, 4 high risk) balanced 
male vs. female 
For each scenario, asked subjects to estimate the 5-year 
risk of CHD events without any therapy; then estimate 
5-year risk if patient taking lipid lowering agent; then 
on 4 point likert scale if they would recommend that 
the patient take lipid lowering therapy  
Measured accuracy of prediction by dividing subjects 
estimate of risk by the risk obtained from the 
Framingham model- 0.67-1.5 = accurate 
Accuracy of estimates after therapy with lipid lowering 
drugs examined by calculating RRR and comparing it 
against a value of 30% derived from a meta-analysis of 
primary prevention trials—RRR’s between 25 and 40% 
considered accurate 
 
Risk estimates: accurate for only 24% of responses (66% were 
overestimates, 10% were underestimates) 
Proportion of physicians overestimating risk ranged from 33-99% for 
the 12 individual questions  
Proportion of physicians underestimating risk ranged from 0-29% for 
the 12 individual questions 
RRR estimates: 43% of estimates were accurate 
Treatment rec: most physicians recommended treatment with statin 
drugs 
Patient factors effecting degree of overall risk estimation: 
- mean degree of overestimation larger for low risk scenarios, int, high 
risk respectively (7.8x Framingham estimate vs. 2.8x vs. 1.5x)  
- physicians more likely to overestimate risk for patients with very 
high cholesterol levels 
- patients with other CHD risk factors produced smaller over-
estimations than when those factors were absent 
Persell, Zei, 
Cameron, 
Zielinski and 
Lloyd-Jones5 , 
2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physicians 
Survey 
All 202 primary 
care physicians 
who had academic 
affiliation with 
Northwestern 
University’s 
Feinberg School 
of Medicine and 
who cared for 
adults in the fall of 
2008 
 
99 (49%) of the 202 
surveys originally sent 
28% were full time med 
school faculty members 
(rest affiliated with med 
school); 59% male 
All were practicing 
primary care internists 
47% reported >30 hours 
patient care/week 
 
Survey with 5 clinical scenarios—each presented 3 
ways- first with only risk factor info, then with RF info 
+ 10-year coronary risk score based on continuous 
models from Framingham, then with both 10-year and 
lifetime estimates from the Cardiovascular Lifetime 
risk Pooling Project 
Instructed to complete survey only with info provided 
at each step and not to skip ahead or go back (although 
nothing to prohibit them from answering questions out 
of order) 
Each case physicians were asked 3 times: 
(1) would you prescribe low dose ASA  
(2) would you repeat lipid testing at 5 years, 1 year, 6 
months, or 6 weeks or start therapy without retesting 
 (3) at what level would LDL need to remain above on 
retesting 190, 160, 130, 100, or 70 for them to 
prescribe lipid lowering therapy 
 
ASA Prescribing: 
51-91% guideline concurrent with RF info alone 
Adding 10-year risk of 15% improved this 80% to 93% guidelines 
adherent 
Adding low 10-year risk (2-3%) reduced non-guideline concordant 
ASA prescribing 
Adding lifetime risk that was mod-high with low 10-year risk 
increased non-concordant ASA prescribing 
Repeat Lipid Testing: 
LDL not at ATPIII goal, physicians often selected wait time longer 
than recommended 6-months 
Providing high lifetime risk increased immediate prescribing without 
testing (not guideline concordant) from 2-12% in patient who was not 
at goal with low 10-year risk 
Providing high 10-year risk and lifetime risk increased prescribing 
without testing—guideline concordant 
Cases where LDL at goal, physicians rarely waited 5 years for 
retesting 
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Compared physician answers to answers based on 
contemporary guidelines (AHA guidelines for ASA 
and NCEP ATPIII for cholesterol) 
 
Overall, neither provision of 10-year estimates nor provision of 
lifetime estimates changed recs for timing of retesting 
Prescribing Lipid Lowering therapy: 
44-75% of time initiated treatment concordant with guidelines with 
RFs only 
Providing lifetime estimate led more physicians to lower threshold for 
prescribing- not guideline concordant 
Addition of 10 year or 10 year and lifetime risk info led to increase in 
guideline concordant responses 
Eichler, Zoller, 
Tschudi and 
Steurer6 , 2007 
Physicians 
Survey 
Physicians in the 
field of general 
medicine (GP’s 
and specialists for 
general internal 
medicine) working 
in their own 
practice in two 
swiss regions 
1723 total general  
physicians  
 
Recruited a sample of 
772 of which 380 
responded (49.3% 
response) excluded 
24 who stated that they 
did not work as GP 
anymore 356 final 
Most docs 
experienced—median 
time interval since 
medical license 25 years 
63.7 percent work as GP 
 
Surveys were sent to all eligible physicians in one 
region and a sample of eligible physicians from another 
region with a letter explaining the study—second 
mailing after 3 weeks to non-respondents  
 
Contained a set of potential barriers from 3 different 
dimensions: lack of knowledge; distrust; practicability 
aspects 
One open ended question asked for other reasons for 
rarely or never use of prediction rules 
Collected data about frequency of use of prediction 
rules in three categories (often, rarely, never) 
Only physicians who answered never or rarely were 
included 
73.9% (263/356) of GPs reported that they rarely or never used 
cardiovascular prediction rules while 22.5% reported tp use them often 
(13 with missing data) 
Of the 263 who rarely or never used: 
- 58% stated they did not use prediction rules because ―a single risk 
value does not take into account the complex situation of the patient‖ 
- 54% because ―the results of prediction rules may lead to 
overtreatment‖ 
- 51% agreed to the statement ―I do not use prediction rules as I know 
my patients well and can estimate their global risk correctly without a 
prediction rule‖ 
- statements in the dimensions lack of knowledge, of aspects of 
practicability were much less common (4-35%) 
- 57% ―The results of prediction rules are often not helpful for 
decision making in practice‖ 
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Table 2: Evidence Table for Systematic Reviews examining effect of global CHD risk scores on clinical outcomes  
 
Study Authors, Year Study Designs 
Included 
Characteristics of Included 
Studies 
Characteristics of 
Included 
Populations 
Characteristics of 
Intervention 
Main Results 
Sheridan and Crespo
3 
, 
2008 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Any study design (ended up 
with 3 cluster RCT’s, 2 
RCT’s , cross sectional mail 
survey study for benefits; 2 
prospective cohort, 2 RCTs, 
and one cross sectional study 
for harms) 
- global CHD risk calc was specified as 
primary study intervention 
- clear documentation of calc of CHD risk 
score by physician or other healthcare 
provider as part of an individual patient 
encounter 
- one or more of these endpoints used for 
clinical benefit studies: [rates of prescribing 
for ASA, anti-hypertensive meds, lipid 
lowering meds, smoking cessation therapies 
or diet and exercise; physician compliance 
with guidelines for CVD prevention; patient 
adherence with therapy; change in patient 
bp, chol levels, asa use, smoking cessation, 
diet or exercise; rate of CVD events] 
- For clinical harms studies: [assessment of 
the adverse effect of global CHD risk 
calculation spec as primary study goal AND 
one of the following endpoints: general 
health and wellbeing, anxiety and worry, 
depression, or motivation to lower CHD risk 
Of 6 studies looking at clinical benefit, 5 
took place in clinical settings (4 in general 
practice setting, 1 in diabetes referral clinic), 
1 used hypothetical scenarios 
questionnaire—all used some form of 
Framingham derived risk score – 3 provided 
risk scores to the physician 
Number of patients and physicians varies 
widely in each study  
Primary end-points varied widely and NO 
studies addressed actual CVD event rates or 
the effect of risk scores on patient adherence 
Of 5 harms studies- all took place in general 
practice pops—3 used risk scores based on 
epi databases other than framingham 
 
 
All > 18 without known 
CVD- otherwise nothing 
reported 
For the studies on clinical 
benefits: 
- documentation of CHD risk 
score on the front of patient 
chart 
- documentation of CHD risk 
score on the front of patient 
chart, box for physician to check 
action steps + 1 hour seminar on 
CHD risk 
- computerized CHD risk profile 
for patients after baseline 
- computer based clinical 
decision support system + CHD 
risk chart 
- lipid decisions in response to 
20 patient case scenarios if CHD 
risk was calculated by physician 
- 4 hour interactive session on 
CHD risk and risk reduction for 
practitioners; 16 page decision 
support tools on CHD risk to be 
given to patient; 2 scheduled 
consultations to discuss risk 
 
For the studies on clinical 
harms: 
 
Physicians knowledge of global 
CHD risk scores may translate into 
modestly increased prescribing of 
CV drugs and modest short-term 
reductions in CHD risk factors 
 
2 fair quality studies showed that 
physician knowledge of CHD risk is 
associated with increased prescribing 
of cardiovascular drugs in high risk 
(but not all) patients 
2 additional fair quality studies 
showed no effect on their primary 
outcomes but one was underpowered 
and the other focused on prescribing 
of lifestyle changes rather than drigs 
One study showed improved bp in 
high risk patients but no 
improvement in the proportion of 
patients at high risk (high number of 
patient with high baseline risk) 
Other studies too methodologically 
limited  
No studies addressed the effect of 
physician risk calculation on actual 
CHD outcomes 
 
5 studies that examined harms found 
no evidence of patient harm from 
knowledge of CHD risk score when 
they were accompanied by 
counseling or optional scheduled 
follow-up 
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Sheridan, Viera, Krantz, 
Ice, Steinman, Peters, 
Kopin and Lungelow
2 
, 
2010 
All study designs (ended up 
with 3 cluster RCTs, 11 
traditional RCTs, 3 quasi 
experimental studies, 1 open 
label follow-up of an RCT) 
14 took place in clinical settings (9 general 
practice, 5 in specialty clinics), 4 in 
community settings (2 in work sites, 2 in 
individuals homes) 
10 studies provided Framingham risk score, 
6 used other risk score, one did not use 
formal calculator, one gave 4 different risk 
scores 
All studies specified global CHD risk 
presentation as primary intervention of part 
of multi-part intervention 
All studies clearly documented the 
presentation of CHD risk directly to 
individuals and measured an outcome of 
interest (accuracy of risk perception, intent 
to start asa, antihypertensive, lipid lowering 
meds, smoking cessation therapies, diet, or 
exercise, adherance to therapy, or change in 
predicted global CVD risk or CVD event 
rates) 
 
Six studies determined to be of good quality, 
12 of fair quality 
 
 
Adults with no history of 
CVD  
Individuals in nearly all 
studies averages moderate 
(6-10%) to high (>10%) 
risk scores as defined by 
current US asa guidelines 
 
For risk perception outcome: 
- assess risk before and after 
presentation of global risk info 
- assess risk perception with 
global risk pres alone vs. + 
education 
- assess risk perception with 
global risk + counseling 
 
For Intent to start therapy: 
- Global risk info alone 
- Global risk info + education 
- Global risk info + counseling 
- global risk info + results of 
decision analysis 
 
For adherence to therapy: 
- risk + educ vs. educ alone 
 
For change in predicted CHD 
risk: 
- repeated presentations of risk 
info 
- repeated counseling 
 
For Risk Perception: 
Global risk info, alone or with 
accompanying education or 
counseling increases the accuracy of 
perceived risk—evidence suggests 
best expected improvement in 
individuals ability to correctly 
categorize their risk is ~10%  
For intent to start therapy: 
Global risk info with education 
increases intent to start therapy by 
15-20 absolute percentage points- 
larger effect sizes when risk is 
combined with counseling instead of 
education alone 
For adherence to therapy: 
1 cRCT small, non-statistically 
significant increase in adherence to 
decisions to take statins among those 
randomized to risk + education vs. 
education alone.  
Risk + education reduced the number 
of participants missing a dose of 
statins in the past week compared 
with education alone 
For change in predicted CHD risk: 
Mixed effects of global CHD risk 
info on predicted CHD risk—related 
to intensity of intervention 
Repeated global risk presentation or 
counseling showed 0.2-2% 
reductions in 10-year predicted CHD 
risk   
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Table 3: Evidence Table for Systematic Review examining tools available for CHD risk calculation 
 
Study Authors, 
Year 
Study Designs 
Included 
Characteristics of Included 
Studies 
Characteristics of 
Included 
Populations 
Characteristics of 
Intervention 
Main Results 
Sheridan, Pignone, 
and Mulrow1 , 
2003 
All designs—internet 
websites as well 
To identify tools: 
Articles and websites that used the 
Framingham risk equations to generate a 
global CHD risk—expressed either as 
proportion of similar patients who would 
have a CHD event over a defined time period 
OR as the movement of a patient across a 
predefined treatment threshold 
To determine accuracy of tools: 
Articles that compared the performance of 
various Framingham based risk tools to that 
of the continuous framingham equation in 
clinical practice—articles included sen and 
sp or enough info that these could be 
calculated  
To determine feasibility of risk tools in 
clinical practice: 
Articles that provided info on the availability 
of the risk factor info required for calc, 
subjective pref of one tool over another, or 
subjective ease of use 
2 main groups: 
(1) risk charts 
(2) electronic calcs 
(computer programs, 
spreadsheet programs, 
web-based calcs) 
Reviewed each tool to determine 
the required input and to 
characterize its output 
 
For studies reporting accuracy 
and feasibility—abstracted info 
on identity of the risk scorer, 
whether they were blinded to the 
gold standard risk assessment, 
what patient pop was used for 
risk assessment, whether all 
necessary patient data were 
available for the risk calc, what 
reference cutpoint was used to 
distinguish high vs. low risk 
made no attempt to combine into 
a quality score 
 
Risk Charts: 
Generally 2 types: one assigns points to various 
levels of each risk factor then assigns a specific 
risk for the total score of summed rf scores; 
second type arrays info in various combinations 
of columns, rows to allow a specific level of risk 
to be read from the chart, or to reach a treatment 
decision given a pre-defined threshold for tx 
Adv: do not require a comp for use (print), use in 
any setting 
Disadv: may be difficult or time consuming at 
first, not as accurate as some of the calcs, 
spreadsheets 
Tools for PDAs: 
Few tools available 
Slightly less precise than some of the 
spreadsheets 
Portable and easy, fast 
Spreadsheet programs for personal comp: 
Require spreadsheet program to be installed on 
each comp that is used for calculating risk 
Web-based: 
Require internet access 
Generally use full Framingham equations—
results can be printed, put on chart 
Studies that assess accuracy and feasibility of 
various risk calcs: 
In general tools displayed good to excellent sens 
and sp for detection of patients with increased 
CHD risk—only Canadian tool had poor 
accuracy in predicting a risk of greater than 
3%/year 
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Table 4: Quality Ratings Table for Included Survey Studies: Each category was rated 0-2 for each study. 0 = poor, 1 = fair, 2 = good.  
  
Study 
Authors, 
Year 
Source Population 
Adequately Described 
Representative 
Study Population 
Appropriate 
Measurement 
Appropriate 
Analysis 
External Validity Overall Quality 
Score 
Pignone, 
Phillips, 
Elasy and 
Fernandez4 , 
2003 
 
1 
 
1 
 
2 
 
1 
 
0 
 
5 
Persell, Zei, 
Cameron, 
Zielinski and 
Lloyd-Jones5 
, 2010 
 
2 
 
1 
 
1 
 
1 
 
1 
 
6 
Eichler, 
Zoller, 
Tschudi and 
Steurer6 , 
2007 
 
2 
 
2 
 
2 
 
1 
 
1 
 
8 
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Table 5: Quality Ratings Table for Included Systematic Reviews: Each category was rated 0-2 for each study. 0 = poor, 1 = fair, 2 = 
good.  
 
Study 
Authors, 
Year 
Comprehensive 
Literature Search 
Used? 
Appropriate 
Inclusion/Exclusion 
Criteria for Studies 
Based on Clinical 
Question? 
Standard Method 
to Appraise 
Internal Validity 
of Included 
Studies? 
Appropriate 
Analysis? 
Was 
Heterogeneity 
assessed? 
Overall Quality 
Score 
Sheridan and 
Crespo
3 
 
2008 
2 2 2 1 2 9 
Sheridan, 
Viera, 
Krantz, Ice, 
Steinman, 
Peters, Kopin 
and 
Lungelow
2 
,2010 
 
2 
 
2 
 
2 
 
2 
 
2 
 
10 
Sheridan, 
Pignone, and 
Mulrow1 , 2003 
1 2 1 1 2 9 
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IV. Appendix B: Physicians’ Survey 
 
This first section is about your clinical practice. 
 
Do you see patients in the office or other ambulatory care setting? 
o Yes 
o No  <If no, person is not eligible for this survey ----- ―We are sorry, but you must be 
active in office-based patient care to participate.‖ Please click the Submit button below so 
we can remove you from our mailing list. END.> 
 
Please indicate your specialty: 
o Cardiology 
o Family medicine 
o General internal medicine 
o Other _____________________ 
 
Approximately what percent of your work time is spent in office-based patient care? 
o 75% or more 
o Between 50 and 75% 
o Between 25 and 50% 
o Less than 25% 
 
Which of the following best describes your office practice setting? 
o Solo practice 
o Small group practice (2-9 clinicians) 
o Large single specialty group (10+ clinicians) 
o Large multi-specialty group (10+ clinicians) 
o Academic group practice 
o Other _______________________ 
 
Does your office practice use an electronic medical record? 
o Yes 
o No 
 
In your office practice, do you use computers in the exam rooms? 
o Yes 
o No   <SKIP NEXT QUESTION> 
 
<If yes> Are the computers in the exam rooms connected to the Internet? 
o Yes 
o No 
 
Do you use a personal digital assistant (e.g., Palm device, iPhone) when seeing patients in the 
office? 
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o  Yes 
o  No 
 
 
 
This  section is about global coronary heart disease (CHD) risk scores—that is, estimates of 
the likelihood of coronary heart disease events calculated by combining patients’ risk 
factors in an empirical equation-- and tools for their calculation. 
 
Have you heard about tools to calculate a patients overall risk of coronary heart disease in the 
next 10 years (global CHD risk)? 
o Yes 
o No <SKIP REMAINDER OF THIS SECTION> 
 
In terms of 10-year coronary heart disease (CHD) risk, at what level of risk do you consider a 
patient to be ―high risk‖ for CHD events?  
o 3% or above 
o  6% or above 
o  10% or above 
o  15% or above 
o  20% or above 
o  25% or above 
o 50% or above 
 
In terms of 10-year coronary heart disease (CHD) risk, below what level of risk do you consider 
a patient to be ―low risk‖ for CHD events?  
o 3% or less 
o 6% or less 
o  10% or less 
o 15% or less 
o  20% or less 
o  25% or less 
o  30% or less 
o 50% or less 
 
When considering primary prevention of coronary heart disease in adults, how often do you 
obtain a calculation of a patient’s global (overall) coronary heart disease risk?  
o Never 
o Rarely (one to two out of 10 adults)     
o Occasionally (three to five out of 10 adults) 
o Most of the time (six to eight out of 10 adults) 
o Always or nearly always (nine to ten out of 10 adults) 
 
 
<only for ―Never‖ or ―Rarely‖ responders> 
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On a scale of 0 to 9, where 0 is not at all important and 9 is extremely important, rate the 
importance of each of the following reasons why you never or rarely obtain a calculation of a 
patient’s global (overall) coronary heart disease risk 
o I am not familiar enough with how to use the risk calculation 
o I do not find it useful in practice 
o There are no accurate tools available for obtaining the calculation 
o There are no easy to use tools available for obtaining the calculation 
o It is too time consuming 
o I do not think that the calculated heart disease risk is valid for my patient population 
o Other __________________ 
 
<Those who ―never‖ calculate risk skip this question> 
Which one of the following do you most commonly use to obtain a patient’s global (overall) 
coronary heart disease risk estimate? 
o A paper chart 
o A web-based application 
o A non-web-based computer program (e.g., spreadsheet calculator on personal computer) 
o A program on a personal digital assistant  
o Other _________________ 
 
 
 
 
Please indicate your level of agreement or disagreement with the following statements.  
 Strongly 
Agree 
Agree Disagree 
Strongly 
Disagree 
I find global CHD risk calculation useful. 
o o o o 
Global CHD risk calculation wastes time. 
o o o o 
Global risk calculation improves patient 
care. o o o o 
Global CHD risk calculation leads to 
better decisions about whether or not to 
recommend therapies to prevent heart 
disease events. 
o o o o 
Global CHD risk calculation increases 
the likelihood that I will recommend risk-
reducing therapies to prevent heart 
disease. 
o o o o 
 
 
How often do you tell the patient his/her global (overall) coronary heart disease risk estimate? 
o Never 
o Rarely (one to two out of 10 adults for whom I calculate risk)     
o Occasionally (three to five out of 10 adults for whom I calculate risk) 
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o Most of the time (six to eight out of 10 adults for whom I calculate risk) 
o Always or nearly always (nine to ten out of 10 adults for whom I calculate risk) 
 
 
How often do you use the global (overall) coronary heart disease risk estimate to guide your 
recommendations about lipid lowering therapy? 
o Never 
o Rarely (one to two out of 10 adults)     
o Occasionally (three to five out of 10 adults) 
o Most of the time (six to eight out of 10 adults) 
o Always or nearly always (nine to ten out of 10 adults) 
 
How often do you use the global (overall) coronary heart disease risk estimate to guide your 
recommendations about aspirin therapy? 
o Never 
o Rarely (one to two out of 10 adults)     
o Occasionally (three to five out of 10 adults) 
o Most of the time (six to eight out of 10 adults) 
o Always or nearly always (nine to ten out of 10 adults) 
 
 
How often do you use the global (overall) coronary heart disease risk estimate to guide your 
recommendations about blood pressure lowering therapy? 
o Never 
o Rarely (one to two out of 10 adults)     
o Occasionally (three to five out of 10 adults) 
o Most of the time (six to eight out of 10 adults) 
o Always or nearly always (nine to ten out of 10 adults) 
 
A few final questions… 
 
In what year did you graduate from medical school? 
<drop down menu> 
 
Please indicate your sex: 
o Female 
o Male 
 
Which of the following is the closest approximation of the region of the country in which you 
practice? 
o Northeast 
o Southeast 
o Midwest 
o West / West coast 
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V. Appendix C: Manuscript Tables and Figures 
 
 
 
Table 1: Characteristics of Respondents (n=952) 
 
 All Family 
physicians 
(n=390) 
General 
Internists 
(n=272) 
Cardiologists 
(n=290) 
P-
value 
 % % % %  
% Male 73.6 57.8 74.6 94.3 <0.001 
Years in Practice     <0.001 
  > 20 
  10-19 
  <10 
63.1 
18.8 
18.1 
40.2 
26.0 
33.9 
70.2 
19.9 
9.9 
88.0 
8.0 
4.0 
 
Region of country     0.02 
  Northeast 
  South 
  Midwest 
  West 
23.7 
33.2 
24.2 
18.9 
18.3 
34.3 
24.5 
22.9 
25.7 
33.6 
24.2 
16.6 
29.3 
31.4 
23.9 
15.4 
 
Time spent in office based care     <0.001 
  > 75% 
  51-74% 
  50% 
  25-49% 
  <25% 
56.5 
14.7 
8.5 
10.2 
10.0 
71.0 
9.5 
5.6 
9.0 
4.9 
63.5 
11.1 
6.6 
6.6 
12.2 
30.3 
25.1 
14.3 
15.3 
15.0 
 
Practice setting     <0.001 
  Solo Practice 
  Small Group (2-9 clinicians) 
  Large Single Specialty group (10+ 
  clinicians) 
  Large multi-specialty group (10+  
  clinicians) 
  Academic group 
  Other 
12.5 
32.0 
11.8 
 
13.9 
 
20.6 
9.2 
9.7 
36.7 
9.7 
 
13.9 
 
21.8 
8.2 
14.8 
32.6 
4.8 
 
18.5 
 
17.0 
12.2 
14.1 
25.2 
21.0 
 
9.7 
 
22.4 
7.6 
 
Use EMR 59.2 59.4 58.2 59.9 0.91 
Computers in exam rooms 55.5 56.8 54.1 55.2 0.78 
Internet connection for computers in 
exam rooms 
94.1 92.7 95.9 94.3 0.46 
Use PDA 47.4 61.5 36.9 38.1 <0.001 
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Table 2: Percentage of respondents who agree with the given statements regarding Global CHD 
Risk assessment 
 
 All Family 
Physicians 
General 
Internists 
Cardiologists  P- 
value 
 % % % %   
I find global CHD risk calculation useful 
(N=834) 
83.8 85.6 80.9 84.0  0.33 
Global CHD risk calculation wastes time 
(N=811) 
18.7 17.1 18.3 21.4  0.40 
Global risk calculation improves patient care 
(N=825) 
80.9 82.8 80.6 78.5  0.41 
Global CHD risk calculation leads to better 
decisions about whether or not to 
recommend therapies to prevent heart 
disease events  
(N=819) 
81.1 82.8 82.8 77.3  0.19 
Global CHD risk calculation increases the 
likelihood that I will recommend risk-
reducing therapies to prevent heart disease 
(N=809) 
71.2 73.5 73.7 65.9  0.08 
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Table 3: Physicians’ Reports of Using CHD Global Risk Assessment to Guide Primary 
Prevention Pharmacologic Recommendations (N=802) 
 
 All 
 
Family 
Physicians 
General 
Internists 
Cardiologists P- 
value 
 % % % %  
Use global CHD risk estimate to guide lipid 
lowering therapy recommendations  
39.9 36.3 36.9 47.6 0.01* 
 
Use global CHD risk estimate to guide 
aspirin therapy recommendations 
34.9 32.6 34.0 38.7 0.31 
Use global CHD risk estimate to guide blood 
pressure lowering therapy 
recommendations 
32.5 32.4 30.7 34.0 0.75 
Use global CHD risk estimate to guide any 
primary prevention therapy 
recommendation** 
49.4 47.3 46.2 55.2 0.10 
* Significance of pairs tested using Pearsons Chi squared. P<.005 between cardiologists and Family Medicine physicians; p< .008 between 
Cardiologists and General Internists. 
** Based on using risk estimate to guide lipid lowering, aspirin, or BP lowering recommendation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
 
Table 4: Characteristics of Physicians who Report Using CHD Risk Assessment (n=952) 
 
 % P- value 
All 41.4  
Specialty  <0.001* 
  Family medicine 
  Internal medicine 
  Cardiology 
41.7 
31.9 
49.4 
 
Years in practice  0.02 
  > 20 
  10-19 
  <10 
38.9 
49.7 
41.3 
 
Sex:  0.92 
  Male 
  Female 
41.6 
41.2 
 
Region of country:  0.48 
  Northeast 
  Southeast 
  Midwest 
  West/West coast 
44.0 
42.0 
37.0 
43.1 
 
Time spent in Office based patient care:  0.002** 
  > 75% 
  51-74% 
  50% 
  25-49% 
  <25% 
36.3 
50.8 
57.5 
43.7 
40 
 
Office Setting:  0.37 
  Solo practice 
  Small group 
  Large Single Specialty 
  Large Multi-specialty 
  Academic Group 
  Other 
39.4 
42.1 
44.2 
33.1 
45.9 
41.1 
 
Use EMR:  0.71 
  Yes 
  No 
40.9 
42.2 
 
Computers in Exam Rooms:  0.67 
  Yes 
  No 
42.0 
40.6 
 
Internet Connection available for computers in Exam Rooms:  0.53 
  Yes 
  No 
42.5 
36.7 
 
PDA Use:  0.001 
  Yes 
  No 
47.1 
36.2 
 
*Chi squared significance tests between paired groups gave p< .072 between Cardiologists and Family Medicine physicians; p< .0001 between 
Cardiologists and General Internists; and p< .018 between Family Medicine physicians and General Internists.  
** Chi squared significance tests between paired groups gave p< .005 between those spending >75% of time; p< .0001 between those spending 
50% of time on patient care; p< .049 between those spending 25-49% of time on patient care; p< .018 between those spending <25% of time on 
patient care. 
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Figure 1: Physicians’ Perceptions of High vs. Low 10-year CHD risk 
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In terms of 10-year coronary heart disease (CHD) risk, at what level of 
risk do you consider a 1•atient to be "high risk" for CHD events? 
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• Do not Use CHD Risk Scoring 
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In terms of 10-year coronary heart disease (CHD) risk, below what level 
of risk do you consider a 1•atient to be "low risk" for CHD events? 
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10-Year CHD Risk Threshold 
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Figure 2: Guideline Concordant Perceptions of High and Low Risk for CHD Events 
 
 
 
 
 
 
 
 
 
* Risk thresholds are based on current guidelines1-3 with >20% indicating high risk for CHD events over 10 years and <10% indicating low risk 
for CHD events over 10 years.  
** ―Underestimate‖ defined as selecting risk threshold below 20%; ―Overestimate‖ defined as selecting a risk threshold above 20% for ―high 
risk‖. ―Underestimate‖ defined as selecting risk threshold below 10%; ―overestimate‖ defined as selecting a risk threshold above 10% for ―low 
risk‖.  
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Table 5: Physicians’ Ratings of Importance of Reasons for Never or Rarely Calculating Patients’ 
Global CHD Risk, Rated 0-5*  
 All Family 
Physicians 
General 
Internists 
Cardiologists P-value 
I am not familiar enough with how to use 
the risk calculation 
2.0 2.3 2.3 1.3 <0.0001 
I do not find it useful in practice 2.2 1.9 2.0 2.9 <0.0001 
There are no accurate tools available for 
obtaining the calculation 
1.3 1.3 1.4 1.2 0.51 
There are no easy to use tools available 
for obtaining the calculation 
1.8 2.0 1.8 1.5 0.01 
It is too time consuming 2.6 2.8 2.6 2.3 0.02 
I do not think that the calculated heart 
disease risk is valid for my patient 
population 
1.2 1.1 1.2 1.4 0.13 
* ―0‖ is the lowest importance level (not important at all), and ―5‖ is the highest importance level (extremely 
important) 
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VI. Appendix D: Geographic Regions of Respondents vs Nonrespondents  
 
 
 
 Respondents 
(n=987) 
Nonrespondents 
(n=7312) 
West 17.9% 19.8% 
Midwest 23.9% 22.8% 
South 34.7% 33.9% 
Northwest 23.5% 23.5% 
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